


### AMENDMENTS TO THE CLAIMS

The following list of claims will replace all prior claims in the application:

1. (Currently amended) A compound of formula I



wherein

X represents -O-; -S-; -SO-; or -SO<sub>2</sub>-;

W is a ~~six-membered, non benzofused, phenyl or heteroaryl ring, substituted by~~  
~~V in meta or para position non-benzofused phenyl or a six-membered, non-benzofused~~  
~~heteroaryl, wherein the phenyl and heteroaryl are substituted by V in meta or para position;~~

V represents a bond; -(CH<sub>2</sub>)<sub>r</sub>; -A-(CH<sub>2</sub>)<sub>s</sub>; -CH<sub>2</sub>-A-(CH<sub>2</sub>)<sub>t</sub>; -(CH<sub>2</sub>)<sub>s</sub>-A-; -(CH<sub>2</sub>)<sub>2</sub>-A-(CH<sub>2</sub>)<sub>u</sub>-; -A-(CH<sub>2</sub>)<sub>v</sub>-B-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-; -A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-; -A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-B-; -CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-; -O-CH<sub>2</sub>-CH(OCH<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-CH(CH<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-CH(CF<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-C(CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-C(CH<sub>3</sub>)<sub>2</sub>-O-; -O-C(CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-CH(CH<sub>3</sub>)-O-; -O-CH(CH<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-C(CH<sub>2</sub>CH<sub>2</sub>)-O-; or -O-C(CH<sub>2</sub>CH<sub>2</sub>)-CH<sub>2</sub>-O-;

A and B independently represent -O-; -S-; -SO-; or -SO<sub>2</sub>-;

U represents aryl; or heteroaryl;

T represents -CONR<sup>1</sup>-; -(CH<sub>2</sub>)<sub>p</sub>OCO-; -(CH<sub>2</sub>)<sub>p</sub>N(R<sup>1</sup>)CO-; -(CH<sub>2</sub>)<sub>p</sub>N(R<sup>1</sup>)SO<sub>2</sub>-; or

-COO-;

Q represents lower alkylene; or lower alkenylene;

M represents hydrogen; cycloalkyl; aryl; heterocycl; or heteroaryl;

R<sup>1</sup> represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; or cycloalkyl-lower alkyl;

p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3; and

v is the integer 2, 3, or 4;

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts, ~~solvent complexes or morphological forms~~ of the compound.

2. (Currently amended) The compound of formula I according to claim 1, wherein

T represents -CONR<sup>1</sup>-;

Q represents methylene; and

M represents aryl, or heteroaryl;

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts, ~~solvent complexes or morphological forms~~ of the compound.

3. (Currently amended) The compound of formula I according to claim 1, wherein V represents -CH<sub>2</sub>CH<sub>2</sub>O-; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>O-; or -OCH<sub>2</sub>CH<sub>2</sub>O-;

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts, ~~solvent complexes or morphological forms~~ of the compound.

4. (Currently amended) The compound of formula I according to claim 1, wherein W represents a 1,4-disubstituted phenyl group;

or optically pure enantiomers, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts, ~~solvent complexes or morphological forms~~ of the compound.

5. (Currently amended) The compound of formula I according to claim 1, wherein U is a mono-, di-, or trisubstituted phenyl or heteroaryl, whereby the substituents are selected from the group consisting of halogen, lower alkyl, lower alkoxy, and CF<sub>3</sub>

or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound; or pharmaceutically acceptable salts, ~~solvent complexes or morphological forms~~ of the compound.

6. (Currently amended) The compound according to claim 1 selected from the group consisting of:

[(*rac.*-)](1*R*<sup>+</sup>, 5*S*<sup>+</sup>)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methyl-benzyl)amide,

$[(rac.)-](1R^*, 5S^*)$ -7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3*λ*<sup>6</sup>-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide,

$[(rac.)-](1R^*, 3R^*, 5S^*)$ -7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3*λ*<sup>4</sup>-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide,

$[(rac.)-](1R^*, 3R^*, 5S^*)$ -7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3*λ*<sup>4</sup>-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide,

$[(rac.)-](1R^*, 5S^*)$ -7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxy-propoxy)-3-methylpyridin-4-ylmethyl]amide, and

$[(rac.)-](1R^*, 5S^*)$ -7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3*λ*<sup>6</sup>-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide.

7. (Previously presented) A pharmaceutical composition comprising at least one compound of claim 1 and a carrier and/or an adjuvant.

8-10. (Cancelled).